Torben Nielsen assumes the position as CEO of Boule Diagnostics as of 16 April 2024

As previously announced, Torben Nielsen is appointed new President and CEO of Boule Diagnostics AB. He will assume the position as of 16 April 2024, succeeding Jesper Söderqvist who at the same time leaves Boule Diagnostics AB.

Torben Nielsen most recently held the position as Executive Vice President in the Analytical Solutions and Customer Enablement business area at PerkinElmer. He brings extensive experience from the hematology market, having worked at Radiometer from 2005 to 2019. His roles included General Manager for Radiometer America and previously Sales Manager for Western Europe. Nielsen also has broader experience in the medical technology industry, having served as Sales Manager for EMEA in the subsidiary companies Ormco and Spark within the Envista group.

For more information, please contact:
Torben Jörgensen, Chairman of Boule Diagnostics AB, torben.jorgensen@biotage.com

Holger Lembrér, CFO, Boule Diagnostics AB, phone: +46 (0)72-230 77 10, holger.lembrer@boule.com
 

About Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 571 million in 2023 and has more than 200 employees. Sales are conducted globally, predominantly through the company’s 200 or so distributors in over 100 countries, supported by Boule’s own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com

Torben Nielsen assumes the position as CEO of Boule Diagnostics as of 16 April 2024